Reuters

Acomplia, or rimonabant, is tipped by analysts as a future multibillion-dollar-a-year seller, since it can help people both lose weight and quit smoking.
Until now, however, it had been uncertain how comprehensive the next set of clinical results would be. The decision to publish two-year figures was taken by industry analysts as a sign the product was progressing well in tests.

More...

Takeover of Indigenous Garifuna Community Hospital

Menstruation Is Fast Becoming Optional

Rare Disease Traced to Sperm Donor

Crohn's Disease Drug Cleared for Children

5-Month-Old Girls in ICU After Separation

Coroner: Peanut Kiss Didn't Cause Death

Feds Probe Kidney Transplant Program

Supermarkets Urge Families to Dinner Table